Welcome to our dedicated page for Agile Therapeutics news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on Agile Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Agile Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Agile Therapeutics's position in the market.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced it has regained compliance with the Nasdaq minimum bid price requirement after a notification from the Nasdaq Listing Qualifications Department. The company's stock had been below the $1.00 threshold for over 30 days but has maintained a closing bid price of $1.00 or greater for the past 10 consecutive business days, from April 11 to April 24, 2023. However, the company still faces challenges as it received a deficiency letter regarding its stockholders' equity, which must meet a minimum of $2,500,000 for continued listing. Agile has until May 11, 2023, to submit a Compliance Plan to address this equity issue. Failure to comply may lead to further actions, including potential delisting.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced a 1-for-50 reverse stock split approved by its board of directors, effective April 10, 2023, to increase its stock price for compliance with Nasdaq listing requirements. Following the split, the outstanding shares will decrease from approximately 46.6 million to about 932,101 shares, with no fractional shares issued. Stockholders will receive cash for any fractional shares based on the last closing price. The change will also adjust the exercise prices of outstanding stock options and warrants. This decision aims to ensure Agile remains listed on Nasdaq despite previous price challenges.
Agile Therapeutics (Nasdaq: AGRX) reported a significant 33% increase in fourth quarter 2022 net revenue to $4.0 million, compared to $3.0 million in the third quarter. The company's operating expenses decreased by 55% to $9.2 million, contributing to a 165% overall revenue growth for 2022 at $10.9 million. Twirla demand surged by 25%, and factory sales rose by 31% in Q4 2022. Agile maintains its expected revenue guidance for 2023 in the $25-$30 million range, highlighting ongoing collaborations to expand its market reach. However, cash reserves dropped to $5.2 million from $19.1 million year-over-year.
FAQ
What is the current stock price of Agile Therapeutics (AGRX)?
